Prosecution Insights
Last updated: November 04, 2026
Application No. 19/532,903

DRUG TO TREAT STIMULANT ADDICTION

Non-Final OA §112
Filed
Feb 06, 2026
Priority
Aug 09, 2023 — provisional 63/518,550 +1 more
Examiner
AZPURU, CARLOS A
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Single Dose Therapeutics Inc.
OA Round
1 (Non-Final)
84%
Grant Probability
Favorable
1-2
OA Rounds
1y 11m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1093 granted / 1305 resolved
+23.8% vs TC avg
Moderate +11% lift
Without
With
+10.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
38 currently pending
Career history
1334
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
24.5%
-15.5% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
30.5%
-9.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1305 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A Preliminary Amendment was filed on 02/06/2026. Information Disclosure Statement An information disclosure statement was filed on 02/20/2026. A Track One Request was granted on 04/10/2026. Election/Restrictions Applicant’s election without traverse of Group I, claims 9-13, 15, 19-25 and 27 in the reply filed on 08/17/2026 is acknowledged. Claims 14, 16-18, 26, and 28-33 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/17/2026. The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant’s use. Arrangement of the Specification As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase “Not Applicable” should follow the section heading: (a) TITLE OF THE INVENTION. (b) CROSS-REFERENCE TO RELATED APPLICATIONS. (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT. (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT. (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A READ-ONLY OPTICAL DISC, AS A TEXT FILE OR AN XML FILE VIA THE PATENT ELECTRONIC SYSTEM. (f) STATEMENT REGARDING PRIOR DISCLOSURES BY THE INVENTOR OR A JOINT INVENTOR. (g) BACKGROUND OF THE INVENTION. (1) Field of the Invention. (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98. (h) BRIEF SUMMARY OF THE INVENTION. (i) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S). (j) DETAILED DESCRIPTION OF THE INVENTION. (k) CLAIM OR CLAIMS (commencing on a separate sheet). (l) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet). (m) SEQUENCE LISTING. (See MPEP § 2422.03 and 37 CFR 1.821 - 1.825). A “Sequence Listing” is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required “Sequence Listing” is not submitted as an electronic document either on read-only optical disc or as a text file via the patent electronic system. The disclosure is objected to because of the following informalities: At page 31, the “Brief Description of the Figures”, should be amended to “Brief Description of the Drawings”. Further, this section should be located after the Brief Summary of the Invention. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 9-13, 15, 19-25, and 27 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) determined that factors which enable an invention. These are: (A) The breadth of the claims; The instant claims set out a treatment for drug withdrawal symptoms using a therapeutic dose of bramantane. (C) The state of the prior art; The art of drug withdrawal treatment is quite extensive. (D) The level of one of ordinary skill; The ordinary practitioner is either a PhD or medical practitioner (E) The level of predictability in the art; As with any treatment for drug withdrawal, patient response to medication is not always predictable. This is especially the case for opioid abuse. (F) The amount of direction provided by the inventor; Applicant provides treatment protocols, including dosage or frequency. (G) The existence of working examples; There are no working examples on the treatment of drug withdrawal for any drugs as well as the efficacy of the treatment. (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. Because each patient response is unique to withdrawal treatment, each one must be evaluated by carefully step by step as to specific drug, dosage, frequency, patient s reaction, efficacy. This involves painstaking, undue experimentation to determine what is efficacious, what if any side effects, and frequency of administration. Treatment of drug withdrawal from opiates requires more stringent protocols than that of marijuana or cocaine, and differs patient to patient. One can not generalize treatment for all drugs, and all patients without painstaking experimentation. The claim for treatment of drug withdrawal is not enabled by the original specification. Conclusion No claims are allowed. US PG-PUB 2009/0175939 (Bosse) is cited for its disclosure of drug withdrawal management. WO 2026183223 is cited for its teaching of using Bromantane in treating withdrawal symptoms from stimulants. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to CARLOS A AZPURU whose telephone number is (571)272-0588. The examiner can normally be reached 9 am- 3 pm, 4 pm-8pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue X Liu can be reached at 571-272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CARLOS A AZPURU/Primary Examiner, Art Unit 1617 caz
Read full office action

Prosecution Timeline

Feb 06, 2026
Application Filed
Oct 15, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778949
ARIPIPRAZOLE SUSTAINED-RELEASE MICROSPHERE AND PREPARATION METHOD THEREFOR
2y 8m to grant Granted Nov 03, 2026
Patent 12758507
METHOD FOR PREPARING DRUG-LOADED SILK FIBROIN NANOCAPSULE, AND PRODUCT THEREOF
4y 9m to grant Granted Oct 13, 2026
Patent 12758531
PHARMACEUTICAL COMPOSITIONS COMPRISING IONIC LIQUIDS
3y 8m to grant Granted Oct 13, 2026
Patent 12757895
RE-OILED AND HYPER-OILED LECITHIN CARRIER VEHICLES
3y 6m to grant Granted Oct 13, 2026
Patent 12758684
IMPLANT FOR OVARIAN DECLINE AND METHODS OF MANUFACTURING AN IMPLANT FOR OVARIAN DECLINE
3y 2m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
84%
Grant Probability
95%
With Interview (+10.9%)
2y 7m (~1y 11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1305 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month